Numbers needed to treat to prevent one primary kidney outcome at three years were 22, 13 and 17, within the ASCVD, HF and high-risk groups, respectively
How the Wegovy Protocol is at Sant Clinics Initial medical consultation : complete clinical history, personal and family history, medication, comorbidities, examination, blood pressure, BMI, abdominal circumference, recent or requested lab tests
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist marketed as Ozempic, Wegovy, and Rybelsus, is FDA-approved for type 2 diabetes and chronic weight management
Adults with a BMI of 27 kg/m or above who also have at least one weight-related condition, such as type 2 diabetes, high blood pressure, or dyslipidaemia
Significant A1c reductions typically become apparent after 1216 weeks of therapy at therapeutic doses
This helps them know if semaglutide is safe and right for you